Written and maintained by CASRAI Editorial Board
Last updated
The Glasgow-Blatchford Score (GBS)—formally the Glasgow-Blatchford Bleeding Score, published in The Lancet in 2000 by Oliver Blatchford, William R. Murray, and Mary Blatchford—is the internationally endorsed pre-endoscopic risk stratification instrument for patients presenting to the emergency department with acute upper gastrointestinal bleeding (UGIB). Unlike the Rockall Score (which was designed to predict mortality and requires esophagogastroduodenoscopy [EGD] for complete calculation), the 0-to-23-point Glasgow-Blatchford Score was specifically derived from 1,748 UGIB admissions to predict a patient’s composite need for clinical intervention: red blood cell transfusion, endoscopic hemostasis, interventional radiology embolization, or surgical repair.
Across emergency departments utilizing the Manchester Triage System, AI scribes for emergency medicine, and gastrointestinal bleeding trials using electronic clinical outcome assessment (eCOA) and HL7 FHIR Observation data pipelines, major clinical practice guidelines—including the 2021 American College of Gastroenterology (ACG), 2021 European Society of Gastrointestinal Endoscopy (ESGE), and 2019 International Consensus Group guidelines—recommend the Glasgow-Blatchford Score as the primary triage tool upon presentation.
How Is the Glasgow-Blatchford Bleeding Score (GBS, 0–23 Points Using BUN, Hemoglobin, Systolic BP, Pulse, Melena, Syncope, Hepatic Disease, Heart Failure) Calculated?
The Glasgow-Blatchford Score is calculated entirely from pre-endoscopic admission data: 2 laboratory biomarkers (blood urea nitrogen [BUN / blood urea] and sex-stratified hemoglobin), 2 vital signs (systolic blood pressure and heart rate), and 4 clinical history/presentation markers (melena, syncope, hepatic disease, and cardiac failure), yielding a total score from 0 to 23 points:
| Admission Parameter (Blatchford et al., Lancet 2000) | Clinical or Laboratory Threshold | Points |
|---|---|---|
| 1. Blood Urea / Blood Urea Nitrogen (BUN) (Max 6 points) |
• Urea < 6.5 mmol/L (BUN < 18.2 mg/dL) | 0 |
| • Urea 6.5 – 7.9 mmol/L (BUN 18.2 – 22.3 mg/dL) | +2 | |
| • Urea 8.0 – 9.9 mmol/L (BUN 22.4 – 27.9 mg/dL) | +3 | |
| • Urea 10.0 – 24.9 mmol/L (BUN 28.0 – 69.9 mg/dL) | +4 | |
| • Urea ≥ 25.0 mmol/L (BUN ≥ 70.0 mg/dL) | +6 | |
| 2a. Hemoglobin — Men (Max 6 points) |
• ≥ 13.0 g/dL (≥ 130 g/L) | 0 |
| • 12.0 – 12.9 g/dL (120 – 129 g/L) | +1 | |
| • 10.0 – 11.9 g/dL (100 – 119 g/L) | +3 | |
| • < 10.0 g/dL (< 100 g/L) | +6 | |
| 2b. Hemoglobin — Women (Max 6 points) |
• ≥ 12.0 g/dL (≥ 120 g/L) | 0 |
| • 10.0 – 11.9 g/dL (100 – 119 g/L) | +1 | |
| • < 10.0 g/dL (< 100 g/L) | +6 | |
| 3. Systolic Blood Pressure (SBP) (Max 3 points) |
• ≥ 110 mmHg | 0 |
| • 100 – 109 mmHg | +1 | |
| • 90 – 99 mmHg | +2 | |
| • < 90 mmHg | +3 | |
| 4. Other Clinical Markers (Sum all present; Max 8 points) |
• Pulse (Heart Rate) ≥ 100 beats per minute | +1 |
| • Presentation with melena (black, tarry stools) | +1 | |
| • Presentation with syncope | +2 | |
| • History or clinical/laboratory evidence of hepatic disease | +2 | |
| • History or clinical evidence of cardiac failure (heart failure) | +2 |
Why Do ACG, ESGE, and International Consensus Guidelines Recommend GBS = 0 or ≤1 to Identify Very-Low-Risk Upper GI Bleeding Patients Safe for Outpatient Management?
In the landmark 3,012-patient prospective international multicenter cohort study by Adrian J. Stanley, Loren Laine, and colleagues (BMJ 2017) comparing all major UGIB risk scores across hospitals in the US, UK, Europe, Asia, and Oceania, the Glasgow-Blatchford Score achieved an area under the receiver operating characteristic curve (AUROC) of 0.86 for predicting the composite need for hospital-based intervention (transfusion, endoscopic therapy, interventional radiology, surgery) or 30-day mortality—significantly outperforming Pre-Endoscopic Rockall (AUROC 0.66) and AIMS65 (AUROC 0.68).
Specifically, at a threshold of GBS ≤ 1:
- Sensitivity & Negative Predictive Value (NPV): A cutoff of
GBS ≤ 1identified nearly twice as many very-low-risk patients (~19.2% of all UGIB presentations) asGBS = 0, while maintaining a sensitivity of 98.6% and a negative predictive value (NPV) of 96.6% for hospital-based intervention or death (with a 30-day mortality rate < 0.4%). - Guideline Endorsement: Based on these data, the 2021 ACG Clinical Guideline (Laine et al.), the 2021 ESGE Guideline (Gralnek et al.), and the 2019 International Consensus Group (Barkun et al.) recommend that patients presenting to the ED with acute UGIB who have a
GBS = 0orGBS ≤ 1be discharged directly from the emergency department for outpatient endoscopy rather than admitted to the hospital. Conversely, scores ofGBS ≥ 7identify patients at high probability of requiring endoscopic hemostasis, while scores ofGBS ≥ 12are associated with increased mortality when endoscopy is delayed.
How Does the Pre-Endoscopic GBS Compare with the Rockall Score (Pre- and Post-Endoscopic) and AIMS65 Mortality Score?
While the Glasgow-Blatchford Score is the gold standard for predicting need for intervention and safe ED discharge, two complementary scores—the Rockall Score (Rockall et al., Gut 1996) and AIMS65 (Saltzman et al., Gastrointest Endosc 2011)—were designed to predict in-hospital mortality and rebleeding:
| Comparison Dimension | Glasgow-Blatchford Score (GBS) (Blatchford et al., 2000) |
Rockall Score (Clinical & Complete) (Rockall et al., 1996) |
AIMS65 Score (Saltzman et al., 2011) |
|---|---|---|---|
| Score Range | 0 to 23 points | • Clinical (Pre-EGD): 0 to 7 points • Complete (Post-EGD): 0 to 11 points |
0 to 5 points (1 point per item) |
| Endoscopy Required? | No (100% pre-endoscopic) | Yes for Complete score (adds EGD diagnosis [0–2 pts] and stigmata of recent hemorrhage [0–2 pts] to Age [0–2], Shock [0–2], and Comorbidity [0–3]) | No (100% pre-endoscopic bedside lab/clinical score) |
| Core Variables | BUN, Hemoglobin (sex-specific), SBP, HR ≥100, Melena, Syncope, Hepatic disease, Heart failure | Age (<60, 60–79, ≥80), Shock (HR ≥100, SBP <100), Comorbidities (CHF/IHD, renal/liver failure, metastatic cancer) + EGD findings | • Albumin < 3.0 g/dL (+1) • INR > 1.5 (+1) • Mental status altered (GCS < 14) (+1) • Systolic BP ≤ 90 mmHg (+1) • 65: Age > 65 years (+1) |
| Primary Validated Endpoint | Composite need for clinical intervention (transfusion, endoscopic therapy, surgery) & safe ED discharge | Rebleeding and 30-day mortality (Complete score ≤ 2 indicates <5% rebleeding and <0.2% mortality after EGD) | In-hospital 30-day mortality, ICU admission, and hospital length of stay (AIMS65 ≥ 2 marks high mortality risk) |
Frequently Asked Questions
How is the Glasgow-Blatchford Bleeding Score (GBS, 0–23 points using BUN, hemoglobin, systolic BP, pulse, melena, syncope, hepatic disease, heart failure) calculated?
The Glasgow-Blatchford Score (0–23 points) sums pre-endoscopic points for Blood Urea Nitrogen (0 to 6 points for BUN ≥18.2 to ≥70 mg/dL), sex-specific Hemoglobin (men: +1 for 12.0–12.9, +3 for 10.0–11.9, +6 for <10.0 g/dL; women: +1 for 10.0–11.9, +6 for <10.0 g/dL), Systolic Blood Pressure (+1 for 100–109, +2 for 90–99, +3 for <90 mmHg), pulse ≥100 bpm (+1), melena (+1), syncope (+2), hepatic disease (+2), and cardiac failure (+2).
Why do ACG, ESGE, and International Consensus Guidelines recommend GBS = 0 or ≤1 to identify very-low-risk Upper GI Bleeding patients safe for outpatient management?
In large prospective international validation studies (Stanley et al., BMJ 2017), a Glasgow-Blatchford Score of 0 or ≤1 demonstrates 98.6% sensitivity and a 96.6% negative predictive value for excluding the need for blood transfusion, endoscopic hemostasis, surgery, or death, allowing nearly 20% of patients presenting with upper GI bleeding to be safely discharged from the ED for outpatient follow-up.
How does the pre-endoscopic GBS compare with the Rockall Score (pre- and post-endoscopic) and AIMS65 mortality score?
GBS (0–23) is superior for early ED triage because it requires no endoscopy and accurately predicts the need for clinical intervention or transfusion. By contrast, the Complete Rockall Score (0–11) requires endoscopic findings to stratify post-EGD rebleeding and mortality, while the 5-item AIMS65 score (Albumin <3.0, INR >1.5, Mental status altered, SBP ≤90, Age >65) is a rapid pre-endoscopic predictor of in-hospital mortality (high risk at ≥2 points) rather than low-risk outpatient discharge.
